Comparing surgery vs. the Trilogy valve for aortic regurgitation
Part of Heart & circulation clinical trials.
This trial compares a new less-invasive valve replacement (Trilogy TAVR) with standard open-heart surgery for people with significant aortic regurgitation. It aims to see which treatment works better for patients who are eligible for both procedures.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have moderate to severe or severe aortic regurgitation and your doctor says you need a valve replacement.
- You are eligible for both the new Trilogy valve procedure and standard open-heart surgery.
- You are willing to be randomly assigned to either the Trilogy valve or surgery.
- You agree to return for all required follow-up visits after the procedure.
- You are at least 18 years old (or the legal age in your country) and can provide consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares a new catheter-based valve (J-Valve) with open-heart surgery for people with severe aortic regurgitation, a condition where the aortic valve doesn't close tightly. It aims to see which treatment is safer and more effective.
This trial tests a less invasive heart valve replacement (TAVR) for people with a leaky aortic valve (aortic regurgitation). It uses ultrasound guidance to place the new valve, which may offer a treatment option for those who cannot have open-heart surgery.
This trial tests whether a new valve replacement procedure (TAVR) is safe and effective for people with severe aortic regurgitation, a leaky heart valve. It is designed for patients who are not good candidates for open-heart surgery because of other health conditions.
This study is testing a new, less invasive heart valve system (TaurusTrio) for people with severe aortic regurgitation (a leaky aortic valve) who cannot have open-heart surgery. It aims to see if the valve is safe and works well to improve symptoms.
This trial is testing a less invasive procedure (TAVR) to fix a leaky aortic valve without open-heart surgery. It's for people with severe aortic regurgitation who are either having symptoms or showing signs of heart strain, and who are not good candidates for traditional surgery.
This trial compares two ways to treat a failing aortic valve that was replaced with a tissue valve during surgery: another surgical replacement or a less invasive catheter-based valve-in-valve procedure. It is for people with low to intermediate surgical risk who are between 18 and 75 years old.
Hear when a new Aortic Regurgitation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.